5 Fast Growers for Your Consideration ( SRPT ) article.
5 Fast Growers for Your Consideration
By Selena Maranjian | More Articles | Save For Later
March 18, 2013 |
Sarepta Therapeutics (NASDAQ: SRPT ) is developing the promising Duchenne muscular dystrophy drug eteplirsen, which may end up winning accelerated FDA approval. My colleague Brian Orelli has explained that the drug affects mRNAs by skipping the part of the gene that contain mutations and that "investors
should keep an eye on RNA therapeutics given their potential to revolutionize medicine." Some wonder whether it will be bought out, while Wall Street's interest in the company is growing.